NorthWest Biotherapeutics Inc (NWBO)

[User-840664]

To conclude, stringently designed and executed prospective randomized clinical trials remain the gold standard for evaluation of efficacy of novel treatments. Control of known, but also unknown, confounders are crucial in clinical trials, and the present analyses of the DCVax-L trial offer neither. Further methodological research and definition of standards that ensure adequate scientific rigor is needed to define the possible role of externally controlled clinical trial data for retrospective analyses or within prospective clinical trials. This concerns both healthcare and regulatory decision making in (neuro-)oncology.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076936/

References
1. Weller M, van den Bent M, Preusser M, et al.. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2020; 18(3):170–186. [PMC free article] [PubMed] [Google Scholar]
2. Liau LM, Ashkan K, Brem S, et al.. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2022; 17:e225370. doi: 10.1001/jamaoncol.2022.5370. Epub ahead of print. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
3. Liau LM, Ashkan K, Tran DD, et al.. First results on survival
from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16(1):142. [PMC free article] [PubMed] [Google Scholar]
4. Rahman R, Ventz S, McDunn J, et al.. Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 2021;22(10):e456–e465. [PMC free article] [PubMed] [Google Scholar]
5. Mishra-Kalyani PS, Amiri Kordestani L, Rivera DR, et al.. External control arms in oncology: current use and future directions. Ann Oncol. 2022;33(4):376–383. [PubMed] [Google Scholar]
6. Gilbert MR, Dignam JJ, Armstrong TS, et al.. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708. [PMC free article] [PubMed] [Google Scholar]
7. Gilbert MR, Wang M, Aldape KD, et al.. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085–4091. [PMC free article] [PubMed] [Google Scholar]
8. Stupp R, Taillibert S, Kanner A, et al.. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306–2316. [PMC free article] [PubMed] [Google Scholar]
9. Weller M, Butowski N, Tran DD, et al.. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373–1385. [PubMed] [Google Scholar]
10. Stupp R, Hegi ME, Mason WP, et al.. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. [PubMed] [Google Scholar]